Digital Pharma East is just around the corner, and this year’s agenda is jam-packed with valuable content on everything from personalization, to HCP digital targeting, to customer engagement, to business transformation and more. The conference -- held September 17-20 in the heart of Philadelphia -- begins with Digital Future Day
Justin Chase, Intouch EVP of innovation and media, recently sat down to talk with MM&M senior editor Larry Dobrow about the evolution of Intouch, how it has embraced innovation from day one, his own arrival at the agency to build the innovation practice, and how Intouch has applied its AI
Check out Intouch EVP David Windhausen's thoughts on the potential of voice technology in pharma and healthcare for the Forbes Technology Council.
It's still early days for artificial intelligence (AI) in the pharma and healthcare space. So much depends on navigating the regulatory environment, yet great strides are being made ... they're just not quite as sexy as, say, a chatbot or what IBM once promised Watson would be. To learn more
Google recently noted that four out of five people "say digital video helps them learn new things," and for understanding things like artificial intelligence (AI) and where it sits on the Gartner Hype Cycle, video is the go-to teaching format. The Gartner Hype Cycle is published annually, and the
This POV describes Colorado House Bill 19-1131 and how it could affect pharma marketers. The bill requires that any one-to-one communications between pharmaceutical representatives (or anyone communicating on their behalf) and prescribers must include written information about the wholesale cost of a drug, as well as the names of at least three generic equivalents. The law goes into effect on August 2, 2019.
Harmonious collaboration produces the best work from your agencies, but getting everyone to be on the same page can be a challenge. How do you ensure that everyone’s doing their part? How can you work effectively and efficiently when there are multiple players, multiple meetings and – more than likely
Last fall, we published a POV called “Should Pharma Care About California’s New Data Privacy Law?” Since then, we’ve been monitoring the legislative process and the discussions and reactions of opinion leaders. This updated POV provides the latest thinking on this law and its implications for pharma marketers.
Data science: a term that always sounds cutting-edge. While discussions of personalized medicine and the related science of gene therapy and similar advances become more science than science fiction, pharma marketing is beginning to step into the individualized, independent experience economy, as well. What is the experience economy? It’s not